STOCK TITAN

Mesoblast Limited American Depositary Shares - MESO STOCK NEWS

Welcome to our dedicated news page for Mesoblast American Depositary Shares (Ticker: MESO), a resource for investors and traders seeking the latest updates and insights on Mesoblast American Depositary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mesoblast American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mesoblast American Depositary Shares's position in the market.

Rhea-AI Summary
Mesoblast Limited reported operational highlights and financial results for the period ended March 31, 2023. The FDA accepted the company's filing for the Biologics License Application (BLA) for remestemcel-L in the treatment of children with steroid-refractory graft versus host disease (SR-aGVHD) and set a goal date of August 2, 2023. The FDA also conducted a pre-license inspection of the manufacturing process for remestemcel-L. Mesoblast received Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) and expects enrollment for the pivotal trial to begin in Q3 2023. The DREAM-HF Phase 3 trial results for rexlemestrocel-L in patients with chronic heart failure were published in the Journal of the American College of Cardiology (JACC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.82%
Tags
none
Mesoblast Limited American Depositary Shares

Nasdaq:MESO

MESO Rankings

MESO Stock Data

822.45M
796.57M
0.75%
2.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Melbourne

About MESO

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf